Want to see TCRT full AI Analyst Report?
Alaunos Therapeutics (TCRT) Ratios
Alaunos Therapeutics Ratios
TCRT's free cash flow for Q2 2026 was $-300.00K. For the 2026 fiscal year, TCRT's free cash flow was increased by $0.00 and operating cash flow was $-300.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 |
| Quick Ratio | 2.45 | 3.98 | 4.22 | 1.65 | 4.91 |
| Cash Ratio | 1.70 | 1.58 | 3.10 | 1.62 | 4.74 |
| Solvency Ratio | -5.13 | -6.76 | -16.78 | -1.33 | -2.07 |
| Operating Cash Flow Ratio | -3.53 | -7.18 | -15.41 | -1.21 | -3.83 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -1.69 | -7.15 |
| Net Current Asset Value | $ 1.18M | $ 2.06M | $ 6.30M | $ 27.42M | $ 42.02M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.31 | 0.32 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.52 | 0.52 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.34 | 0.34 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
| Financial Leverage Ratio | 1.38 | 1.34 | 1.31 | 1.68 | 1.63 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -16.09 | -1.55 | -7.66 |
| Interest Coverage Ratio | 0.00 | 0.00 | -17.84 | -11.13 | -65.22 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.12 | 0.11 |
| Interest Debt Per Share | 0.00 | 0.00 | 1.20 | 16.04 | 21.89 |
| Net Debt to EBITDA | 0.33 | 0.23 | 0.20 | 0.60 | 0.61 |
| Profitability Margins | |||||
| Gross Profit Margin | -27160.00% | 100.00% | -95960.00% | 100.00% | 100.00% |
| EBIT Margin | -83520.00% | -46790.00% | -664380.00% | -1183.30% | -19487.94% |
| EBITDA Margin | -83380.00% | -46770.00% | -618080.00% | -1088.88% | -18835.43% |
| Operating Profit Margin | -84500.00% | -48120.00% | -685340.00% | -1201.40% | -19484.67% |
| Pretax Profit Margin | -83520.00% | -46790.00% | -702800.00% | -1291.24% | -19786.68% |
| Net Profit Margin | -83520.00% | -46790.00% | -702800.00% | -1291.24% | -19786.68% |
| Continuous Operations Profit Margin | -83520.00% | -46790.00% | -702800.00% | -1291.24% | -19786.68% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.84% | 97.24% | 102.55% | 107.48% | 101.55% |
| Return on Assets (ROA) | -140.80% | -169.84% | -425.27% | -58.10% | -83.01% |
| Return on Equity (ROE) | -193.96% | -226.81% | -557.16% | -97.86% | -135.64% |
| Return on Capital Employed (ROCE) | -196.24% | -233.25% | -543.32% | -86.10% | -98.38% |
| Return on Invested Capital (ROIC) | -196.24% | -233.25% | -543.32% | -59.85% | -87.97% |
| Return on Tangible Assets | -140.80% | -169.84% | -425.27% | -58.10% | -83.01% |
| Earnings Yield | -66.36% | -152.99% | -207.06% | -26.77% | -33.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.67 | 2.00 | 5.00 | 730.50 | 0.36 |
| Payables Turnover | 2.22 | 0.00 | 7.80 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.05 | 0.00 | 2.50 | 0.28 | 0.03 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
| Cash Conversion Cycle | 54.84 | 182.50 | 26.19 | 0.50 | 1018.88 |
| Days of Sales Outstanding | 219.00 | 182.50 | 73.00 | 0.50 | 1018.88 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 164.16 | 0.00 | 46.81 | 0.00 | 0.00 |
| Operating Cycle | 219.00 | 182.50 | 73.00 | 0.50 | 1018.88 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.47 | -3.10 | -18.84 | -20.19 | -43.00 |
| Free Cash Flow Per Share | -1.52 | -3.10 | -18.97 | -20.34 | -45.33 |
| Dividend Paid and CapEx Coverage Ratio | -29.28 | 0.00 | -153.01 | -135.33 | -18.50 |
| Capital Expenditure Coverage Ratio | -29.28 | 0.00 | -153.01 | -135.33 | -18.50 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -1.46 | -2.04 |
| Operating Cash Flow to Sales Ratio | -573.80 | -497.10 | -6028.40 | -10.00 | -154.44 |
| Free Cash Flow Yield | -47.15% | -162.54% | -178.77% | -20.89% | -27.72% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.47 | -0.65 | -0.48 | -3.74 | -2.97 |
| Price-to-Sales (P/S) Ratio | 1258.64 | 305.84 | 3394.19 | 48.24 | 587.17 |
| Price-to-Book (P/B) Ratio | 2.92 | 1.48 | 2.69 | 3.66 | 4.03 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.12 | -0.62 | -0.56 | -4.79 | -3.61 |
| Price-to-Operating Cash Flow Ratio | -2.19 | -0.62 | -0.56 | -4.82 | -3.80 |
| Price-to-Earnings Growth (PEG) Ratio | 0.06 | 0.01 | 0.03 | 0.07 | 0.64 |
| Enterprise Value Multiple | -1.18 | -0.42 | -0.35 | -3.83 | -2.50 |
| Enterprise Value | 4.91M | 1.97M | 10.91M | 121.96M | 187.73M |
| EV to EBITDA | -1.18 | -0.42 | -0.35 | -3.83 | -2.50 |
| EV to Sales | 981.64 | 196.74 | 2181.79 | 41.74 | 471.70 |
| EV to Free Cash Flow | -1.65 | -0.40 | -0.36 | -4.14 | -2.90 |
| EV to Operating Cash Flow | -1.71 | -0.40 | -0.36 | -4.17 | -3.05 |
| Tangible Book Value Per Share | 1.11 | 1.29 | 3.94 | 26.63 | 40.62 |
| Shareholders’ Equity Per Share | 1.11 | 1.29 | 3.94 | 26.63 | 40.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.00 | 2.02 | 0.28 |
| Net Income Per Share | -2.14 | -2.92 | -21.97 | -26.07 | -55.10 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.06 | 1.09 | 1.02 |
| Research & Development to Revenue | 272.60 | 36.20 | 3255.80 | 8.56 | 124.73 |
| SG&A to Revenue | 573.40 | 446.00 | 2443.80 | 4.50 | 69.26 |
| Stock-Based Compensation to Revenue | 82.80 | 43.50 | 560.00 | 1.21 | 27.07 |
| Income Quality | 0.69 | 1.06 | 0.86 | 0.77 | 0.78 |
Currency in USD
